If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Proposed Placing

11 Jun 2012 08:00

RNS Number : 0479F
Imaginatik PLC
11 June 2012
 

11 June 2012

Imaginatik Plc

 

("Imaginatik" or the "Company")

 

PROPOSED PLACING AND NOTICE OF GENERAL MEETING

 

Imaginatik plc (AIM: IMTK.L), the world's first full service innovation provider offering a range of technology products and consultancy, announces that it is proposing to raise up to £1million before expenses through a conditional placing of up to 333,333,333 new ordinary shares (the "Placing Shares") with institutional and other investors at a price of 0.3p per Placing Share (the "Placing"). The Company has received irrevocable commitments to subscribe for 285,833,333 Placing Shares and expressions of interest from certain Directors of the Company to subscribe for a further 47,500,000 Placing Shares in the Placing on the same terms. The Placing is being arranged by Northland Capital Partners Limited ("Northland") subject to the terms of a conditional agreement between the Company and Northland (the "Placing Agreement")

 

The Placing Shares will represent approximately 39 per cent. of the enlarged issued share capital of the Company.

 

Use of proceeds

 

Subject to the Placing Agreement becoming unconditional and not being terminated in accordance with its terms, the Placing will raise up to £1 million before the deduction of expenses payable by the Company. The net proceeds will be used to expand the Company's US based sales team, to add consultancy capacity in both the US and European markets, to further invest in the Company's technology and further develop its branding and marketing efforts.

 

Matt Cooper, Chairman of Imaginatik, commented:

 

"We are delighted with the support from new and existing investors. These funds will enable us to complete the transition from a software provider to the world's first full service innovation company and give us the platform from which to capitalise on this unique position in the market."

 

Related party transactions

 

The following shareholders, each of whom is a related party for the purposes of the AIM Rules by virtue of the extent of their interests in the existing ordinary shares, has agreed to subscribe for Placing Shares at the Placing Price as follows:

 

 

Percentage of existing ordinary shares held prior to the Placing

 

 

 

 

 

Placing participation

 

 

 

 

Number of Placing Shares to be acquired

 

 

Percentage of issued ordinary shares after Completion

Artemis Investment Management

 

15.37

£125,000

41,666,667

13.68

Octopus Asset Management

12.84

£50,000

16,666,667

9.37

 

The Board, other than Matt Cooper who as chairman of Octopus Asset Management is not independent for the purpose of the AIM Rules, considers, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, that the participation in the Placing by Artemis Investment Management and Octopus Asset Management is in each case fair and reasonable so far as the shareholders of the Company are concerned.

 

Notice of General Meeting

 

The Placing is conditional, inter alia, on the approval of Imaginatik's shareholders and admission of the Placing Shares to trading on AIM. A circular containing a notice of the General Meeting is today being sent to Imaginatik's shareholders with details of the Placing and seeking the necessary approval of shareholders for the issue of the Placing Shares. The General Meeting will be held at the offices of Marriott Harrison, Staple Court, 11 Staple Inn Buildings, London WC1V 7QH at 11.00am on Wednesday 27 June 2012. A copy of the circular will be available on the Company's website; www.imaginatik.com.

 

The Placing Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions declared on or after the date on which they are issued.

 

Application will be made for admission of the Placing Shares to trading on AIM ("Admission") and, subject to the requisite shareholder approval for the Placing being obtained at the General Meeting, it is expected that Admission will be effective on or around 8.00 am on 28 June 2012.

 

 

For further information please contact:

 

Imaginatik plc Tel: 020 7917 2975

Matt Cooper, Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

John Howes / Alice Lane (Broking)

Newgate Threadneedle Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

 

About Imaginatik

Imaginatik provides a range of Innovation solutions comprised of consultancy, enterprise software and program management to deliver innovation results to companies such as The World Bank, NYSE, The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. Imaginatik's mission is to help these companies build sustainable innovation competencies.

 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Winchester, UK. For more information visit www.imaginatik.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFMMPTMBABBAT
Date   Source Headline
19th Dec 20083:16 pmRNSDirector/PDMR Shareholding
18th Dec 20089:45 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSShare Option Schemes
1st Dec 20087:00 amRNSDirector's Disclosure Update
19th Nov 200812:39 pmRNSDirectors Dealing
13th Nov 20087:00 amRNSInterim Results
14th Oct 20087:00 amRNSTrading Statement
2nd Oct 20087:00 amRNSContract Win
30th Sep 20084:30 pmRNSTotal Voting Rights
24th Sep 20087:00 amRNSDirector/PDMR Shareholding
15th Sep 20087:00 amRNSContract Win
3rd Sep 20087:00 amRNSIssue of Equity
21st Aug 20087:00 amRNSContract Win
28th Jul 20089:27 amRNSNon-Executive Retirement
10th Jul 200810:20 amRNSResult of AGM
10th Jul 20087:00 amRNSAGM Statement
24th Jun 20087:00 amRNSDirector/PDMR Shareholding
18th Jun 200810:05 amRNSAnnual Report and Accounts
13th Jun 200812:16 pmRNSDirector/PDMR Shareholding
11th Jun 20087:00 amRNSFinal Results
1st Apr 200811:52 amRNSDirector Dealings
31st Mar 20084:30 pmRNSTotal Voting Rights
17th Mar 20082:57 pmRNSShare Subscription - Update
10th Mar 20082:23 pmRNSShare Subscription
10th Mar 20089:30 amRNSHolding(s) in Company
28th Feb 200810:01 amRNSPfizer Update
13th Feb 20089:40 amRNSTrading Statement
22nd Jan 20089:30 amRNSWorld Economic Forum
11th Jan 200810:13 amRNSMajor Contract Wins
30th Nov 20072:41 pmRNSWEF Technology Pioneer
14th Nov 20072:12 pmRNSInterim Results
16th Aug 200711:05 amRNSAgreement With IBM
14th Aug 20074:55 pmRNSAIM Rule 26 Information
27th Jul 200710:46 amRNSAGM Statement
27th Jul 20077:01 amRNSAGM Statement
11th Jul 200712:00 pmBUSGlobal Competition Forces Innovation and Collaboration Acceleration
29th Jun 20073:33 pmRNSAnnual Report and Accounts
13th Jun 200711:50 amRNSResult of EGM
12th Jun 20077:02 amRNSFinal Results
4th Jun 20077:02 amRNSUK & European Contract Wins
1st Jun 200710:29 amRNSNotice of Results
18th May 200710:05 amRNSNotice of EGM
23rd Apr 20072:38 pmBUSImaginatik Wins a Queens Award for Enterprise
23rd Apr 200711:02 amRNSWins A Queens Award
19th Apr 200710:59 amRNSDirector/PDMR Shareholding
21st Mar 20077:04 amRNSSenior Management Appointment
21st Mar 20077:01 amBUSImaginatik Appoints President, Americas and New CMO to Accommodate Growth
16th Mar 200711:45 amRNSTrading Statement
9th Feb 200711:30 amBUSImaginatik Appoints Managing Director in United Kingdom
9th Feb 20077:00 amRNSAppointment of UK MD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.